Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Abbott Next Generation Drug Eluting Stent 48mm Study

NCT04282148 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this SPIRIT 48 study is to evaluate the safety and effectiveness of the ABT NG DES 48 in improving coronary artery luminal diameter in subjects with coronary artery disease (CAD) due to de novo native coronary artery long lesions.

Conditions Studied

Interventions

  • DEVICE ABT NG DES 48 EECSS

Study Locations (20)

California

  • Scripps Memorial Hospital - La Jolla — La Jolla
  • UCLA Medical Center Santa Monica — Santa Monica

Florida

  • The Cardiac & Vascular Institute Research Foundation, LLC — Gainesville
  • Shands at the University of Florida — Gainesville

Kansas

  • Via Christi Regional Medical Center - St. Francis Campus — Wichita
  • Cardiovascular Research Institute of Kansas — Wichita

Ohio

  • The Lindner Center — Cincinnati
  • St. Vincent Mercy Medical Center — Toledo

Texas

  • Baylor Scott & White Heart & Vascular Hospital — Dallas
  • The Heart Hospital Baylor Plano — Plano

Arizona

  • HonorHealth — Scottsdale

Massachusetts

  • Massachusetts General Hospital — Boston

Minnesota

  • Minneapolis Heart Institute — Minneapolis

Trial Details

FieldValue
Enrollment Target 107 participants
Start Date 2020-06-17
Est. Completion 2023-09-17
Phase NA

Sponsor

Abbott Medical Devices

155 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04282148

The ClinicalTrials.gov registry entry for NCT04282148 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 155 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention — of which ABT NG DES 48 EECSS is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04282148 reports 20 study locations spanning 15 distinct geographic areas — top geographies include California, Florida, Kansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04282148 about?

NCT04282148 is a clinical study titled "Abbott Next Generation Drug Eluting Stent 48mm Study". The purpose of this SPIRIT 48 study is to evaluate the safety and effectiveness of the ABT NG DES 48 in improving coronary artery luminal diameter in subjects with coronary artery disease (CAD) due to de novo native coronary artery long lesions.

What is the current status of trial NCT04282148?

This trial is currently completed. It is a NA study. The enrollment target is 107 participants. The study started on 2020-06-17. Estimated completion is 2023-09-17.

What conditions does trial NCT04282148 study?

This clinical trial studies the following conditions: Coronary Artery Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04282148?

The interventions under investigation include: ABT NG DES 48 EECSS (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04282148?

This trial is sponsored by Abbott Medical Devices, which has 155 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04282148 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial